Your browser is no longer supported. Please, upgrade your browser.
Settings
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own3.90% Shs Outstand93.39M Perf Week-3.17%
Market Cap385.01M Forward P/E- EPS next Y-1.24 Insider Trans-11.73% Shs Float61.59M Perf Month-23.21%
Income-146.20M PEG- EPS next Q-0.40 Inst Own55.00% Short Float21.50% Perf Quarter-65.95%
Sales144.40M P/S2.67 EPS this Y-2.80% Inst Trans-6.35% Short Ratio4.17 Perf Half Y-68.32%
Book/sh1.93 P/B2.06 EPS next Y16.30% ROA-42.10% Target Price- Perf Year-50.56%
Cash/sh2.15 P/C1.85 EPS next 5Y- ROE-81.70% 52W Range3.76 - 15.24 Perf YTD-64.10%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-42.00% 52W High-73.95% Beta0.64
Dividend %- Quick Ratio4.20 Sales past 5Y59.60% Gross Margin34.00% 52W Low5.59% ATR0.29
Employees593 Current Ratio4.70 Sales Q/Q-36.60% Oper. Margin-92.80% RSI (14)31.82 Volatility6.50% 6.91%
OptionableYes Debt/Eq0.83 EPS Q/Q-91.60% Profit Margin- Rel Volume0.51 Prev Close4.12
ShortableYes LT Debt/Eq0.82 EarningsMar 01 BMO Payout- Avg Volume3.17M Price3.97
Recom2.40 SMA20-8.53% SMA50-46.58% SMA200-63.84% Volume1,617,027 Change-3.64%
Mar-02-21Downgrade Truist Buy → Hold $6
Mar-02-21Downgrade SVB Leerink Outperform → Mkt Perform $22 → $5
Mar-02-21Downgrade Oppenheimer Outperform → Perform
Mar-02-21Downgrade JP Morgan Overweight → Neutral $7
Mar-01-21Downgrade Needham Buy → Hold
Feb-10-21Initiated Evercore ISI Outperform
Oct-26-20Initiated SVB Leerink Outperform $22
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Apr-17-21 01:45PM  
Apr-16-21 11:00PM  
05:52PM  
04:25PM  
03:15PM  
02:30PM  
12:00PM  
11:35AM  
Apr-15-21 05:05PM  
05:00PM  
04:40PM  
06:30AM  
Apr-14-21 11:07PM  
05:50PM  
05:01PM  
04:39PM  
04:00PM  
11:30AM  
11:00AM  
11:00AM  
11:00AM  
Apr-13-21 06:10PM  
06:00PM  
05:35PM  
07:30AM  
06:45AM  
Apr-12-21 09:42PM  
08:15PM  
07:48PM  
07:14PM  
01:25PM  
01:00PM  
10:30AM  
10:00AM  
06:30AM  
Apr-10-21 08:19PM  
03:00PM  
Apr-09-21 01:28PM  
12:00PM  
Apr-08-21 04:55PM  
04:30PM  
10:30AM  
10:00AM  
06:30AM  
01:00AM  
Apr-07-21 06:25PM  
05:00PM  
04:00PM  
02:46PM  
06:30AM  
Apr-06-21 10:44PM  
06:13PM  
04:40PM  
04:00PM  
12:28PM  
11:00AM  
06:30AM  
05:30AM  
Apr-05-21 02:00PM  
01:35PM  
Apr-04-21 10:55PM  
10:05PM  
Apr-03-21 04:30PM  
Apr-02-21 03:40PM  
12:10PM  
12:00PM  
11:30AM  
06:30AM  
Apr-01-21 10:12PM  
07:54PM  
11:00AM  
10:05AM  
06:30AM  
01:00AM  
Mar-31-21 05:30PM  
05:00PM  
12:30PM  
12:15PM  
12:00PM  
08:45AM  
08:00AM  
Mar-30-21 04:33PM  
03:55PM  
11:55AM  
11:00AM  
Mar-29-21 09:52PM  
06:23PM  
12:46PM  
Mar-28-21 10:55PM  
Mar-27-21 04:45PM  
10:00AM  
Mar-26-21 02:17PM  
12:45PM  
12:30PM  
06:30AM  
Mar-25-21 11:20PM  
02:15PM  
01:56PM  
11:30AM  
11:05AM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAMPBELL KIMDirectorApr 05Buy4.428,25036,4658,250Apr 07 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 22Option Exercise4.5510,00045,5003,212,959Mar 22 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Option Exercise4.5520,00091,0003,202,959Mar 19 04:12 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Option Exercise4.5520,00091,0003,182,959Mar 17 05:02 PM
Zuo William WeiPresident, China DivisionMar 04Sale4.52419,9311,898,088142,883Mar 08 04:39 PM
WU JINNDirectorMar 03Sale4.7598,000465,500303,208Mar 04 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 09Option Exercise4.5510,00045,5003,162,959Dec 09 05:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 01Buy13.311,00013,3103,152,959Dec 01 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 10Buy11.951,00011,9503,151,959Nov 10 04:10 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 06Buy11.705,00058,5003,150,959Nov 06 06:36 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 24Buy11.951,00011,9503,145,959Sep 24 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 21Buy12.421,00012,4203,144,959Sep 21 04:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy11.001,800,00019,800,00013,532,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 14Buy11.951,00011,9503,143,959Sep 14 04:09 PM
Fok MansonDirectorSep 12Buy11.0316,491181,8961,999,609Sep 14 04:21 PM
Fok MansonDirectorSep 11Buy11.3913,509153,8681,983,118Sep 14 04:21 PM
WU JINNDirectorSep 11Buy11.0510,000110,500401,208Sep 14 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.911,00010,9103,142,959Sep 14 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.992,00021,9783,141,959Sep 11 04:10 PM
YORDON JEFFREYSee RemarksSep 10Option Exercise11.0018,180199,980237,106Sep 10 04:44 PM
Kanfer JordanDirectorSep 10Buy11.494505,1704,634Sep 11 04:20 PM
WU JINNDirectorSep 10Buy11.1520,000223,000391,208Sep 11 04:16 PM
Sze RandollChief Financial OfficerSep 10Buy11.401,00011,4006,000Sep 10 04:48 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 10Buy11.2210,000112,2003,139,959Sep 10 04:38 PM
Davis Stephanie ADirectorSep 10Buy11.3510,000113,50020,000Sep 14 04:24 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 10Buy11.24200,0002,248,00011,732,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 21Option Exercise4.555,00022,7503,129,959Aug 21 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 20Option Exercise4.5510,00045,5003,124,959Aug 20 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerJun 22Buy12.821,00012,820143,299Jun 23 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardJun 22Buy12.812,00025,6203,114,959Jun 22 04:08 PM